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Abstract Infective endocarditis despite advances in diag-
nosis remains a common cause of hospitalization, with high
morbidity and mortality rates. Through literature review it is
possible to conclude that polymicrobial endocarditis occurs
mainly in intravenous drug abusers with predominance in
the right side of the heart, often with tricuspid valve in-
volvement. This fact can be associated with the type of drug
used by the patients; therefore, knowledge of the patient's
history is critical for adjustment of the therapy. It is also
important to emphasize that the most common combinations
of organisms in polymicrobial infective endocarditis are:
Staphylococcus aureus, Streptococcus pneumonia and
Pseudomonas aeruginosa, as well as mixed cultures of
Candida spp. and bacteria. A better understanding of the
epidemiology and associated risk factors are required in order
to develop an efficient therapy, although PE studies are diffi-
cult to perform due to the rarity of cases and lack of prospec-
tive cohorts.
Introduction
Infective endocarditis (IE) despite advances in diagnosis
remains a usual cause of hospitalization, with high morbid-
ity and mortality rates. According to the Guidelines on
Prevention, Diagnosis and Treatment of Infective Endocar-
ditis report [1], IE is defined as “an endovascular microbial
infection of cardiovascular structures including endarteritis
of the large intrathoracic vessels or of intracardiac foreign
facing the bloodstream.”
IE still is an important clinical problem that can lead to
native valve endocarditis (NVE) and prosthetic valve endo-
carditis (PVE) with an annual incidence of approximately
1.7–6.2 cases per 100,000 patients [2]. PVE has an alarming
mortality rate of 40–50 %, being more frequent in men than
women (in a ratio of 2:1), and the occurrence gradually
increases with age. The management of IE is a challenge
because the usually proposed standard antibiotics often are
not very efficient, which can be attributed to several factors,
namely, allergic reactions, antibiotic toxicity due to pro-
longed therapy and increasing microbial resistance to anti-
biotics used as first-line therapeutic options [3]. In fact, this
high tolerance to antimicrobial treatment is mainly due to
the fact that infective microorganisms are generally in the
biofilm form, i.e., as sessile communities of cells irrevers-
ibly attached to cardiac surfaces and enclosed in a protective
matrix of exopolymeric products [4].
When the infecting organism of NVE is identified, the
treatment of choice is expanded antibiotic therapy. Patients
with PVE most of the time require surgery to replace the
infected prosthesis, as medical treatment alone is generally
insufficient. This failure of antimicrobial treatment is often
related with biofilm formation on the surface of the prosthetic
valve. Biofilms are up to 1000-fold more resistant than plank-
tonic cells and are associated with numerous pathologies, such
as PVE, normally correlated with a more deleterious progno-
sis than NVE. Amongst other causes, improper visualization
of a collection of platelets, fibrin, microorganisms, and
inflammatory cells—the so called “vegetation”—in PVE, in
the transthoracic echocardiography, is responsible for the poor
diagnosis. Even though NVE is significantly more recurrent
than PVE [5], medical treatment for PVE is rarely successful
[6, 7]. Nevertheless, since transoesophageal echocardiography
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was introduced into clinical practice, the diagnostic sensitivity
and specificity for the detection of vegetations located on
prosthetic valves has been improved [8].
IE is mainly caused by Staphylococcus aureus, Pseudo-
monas aeruginosa, streptococci, enterococci, Staphylococ-
cus epidermidis, and the HACEK organisms (Hemophilus
parainfluenzae, Hemophilus aphrophilus, Actinobacillus
[Hemophilus] actinomycetemcomitans, Cardiobacterium
hominis, Eikenella species, and Kingella species) [9]. In
the recent prospective study of Rostagno et al. [7], staphy-
lococci were the more frequent IE etiological agents, in
agreement with previous reports [10]. In fact, in a recent
study, it was concluded that the strongest predictor of
mortality in patients with IE was MRSA infection, followed
by staphylococcal infection, especially in association with
older age and/or with large vegetations [11]. According to
Bouza et al. [12], nosocomial infection contributes to endo-
carditis in 22 % of the cases, with mortality greater than
50 %. Predominant pathogens are staphylococci and entero-
cocci, often related to IVs or surgical procedures, and fewer
than 50 % of patients had underlying structural heart
disease. A particular risk group includes immunosuppressed
patients with CVCs and those undergoing haemodialysis
[13]. Coagulase-negative staphylococci (CNS) are the most
common cause of PVE [14]. It is important to highlight that
Candida and Aspergillus species cause the majority of
fungal IE [15].
The diagnosis of IE is simple in patients with classic
oslerian manifestations: bacteremia or fungemia, evidence of
active valvulitis, peripheral emboli, and immunologic vascu-
lar phenomena. Nevertheless, if the characteristic peripheral
stigmata is discrete or absent, during the acute phase of IE,
particularly among IVDA patients with S. aureus and HA-
CEK [9], and is not detected in time, the final outcome for the
patient will be deleterious.
Despite improvements in health care, the incidence of IE
has not decreased in recent decades and still persists with
substantial morbidity and mortality related to this infection
[13]. This apparent contradiction can be explained by the
fact that there is a progressive development in risk factors:
classic predisposing conditions, such as rheumatic heart
disease (still not eradicated), and new IE risk factors such
as IV drug use, sclerotic valve disease in elderly patients,
use of prosthetic valves, and nosocomial disease. Recently
identified pathogens, which are difficult to grow in vitro, e.g.
Bartonella spp. and Tropheryma whipplei, were found in few
patients, as well as resistant microorganisms to conventional
antimicrobial therapy [16].
Polymicrobial endocarditis (PE) is a variant of IE,
which occurs when the infection is carried out by more
than one organism and, despite being uncommon, is often
fatal, especially when the polymicrobial community includes
Candida species.
Taking into consideration all the facts described previ-
ously, it is important to understand IE and PE pathogenesis
to develop new strategies for their control, including new
drugs and new prosthetic valve materials.
The main goal of this review is to summarize the current
knowledge of IE and PE, especially associated with intrave-
nous drug abuse.
Infective endocarditis of intravenous drug
abusers—IVDA-IE
IE continues to be a preeminent health hazard among IVDAs.
Although the exact incidence of IE in IVDAs is still unknown,
an increase in the number of hospitalization of IVDAs with IE
is noticed [17]. IE related to IVDAs occurs more recurrently in
IVDAs who are HIV positive, particularly those with ad-
vanced immunosuppression [18, 19]. S. aureus is responsible
for most of the IE cases among IVDAs [20]. IVDAs IE
etiology is changing, comprising other staphylococci and
Pseudomonas, as well as pathogenic fungi [21, 22]. The most
commonly isolated fungi are C. albicans (24 %), and non-
Candida albicans accounts for 24 % of the fungal isolates
[21]. Also, due to IVDAs high-risk behaviors, they are sub-
jected to needle-borne infections by organisms that are usually
non-pathogenic. Owing to the habit of cleaning their needles
with saliva and using the saliva to dissolve the drug, IVDAs
are therefore prone to infection from normal oropharyngeal
flora microorganisms (e.g., Haemophilus parainfluenzae,
Eikenella corrodens, and Streptococcus milleri) [23].
Right-sided IE accounts for 5–10% of cases of IE [19], and
it may occur in patients with a permanent pacemaker, implant-
able cardioverter defibrillator, CVC, or congenital heart dis-
ease, although this situation is more common in IVDAs [24].
Among the pathophysiological hypotheses that support the
incidence of right-sided IE in IVDAs are abnormalities on the
immune system, contaminated drug solutions and reduced
injection hygiene [25].
IVDA-IE patients have a high recurrence rate of right-sided
IE and most of these patients develop severe sepsis, conges-
tive heart failure, embolization, or other complications that
lead to organ failure and to intensive care unit admission
(ICU), as well as to surgery [26]. It must be noted that a new
pattern of IE in IVDAs is rising, characterized by infections on
the left side of the heart with a severe clinical course, and
requiring surgery in the active phase [27]. Left-sided endocar-
ditis, in comparison to right, and polymicrobial compared to
single organism, are thus risk factors for an increase in mor-
bidity and mortality in IVDAs with IE [28]. A preponderance
of tricuspid valve involvement seems to exist, but the reason is
still unknown. One of the hypotheses proposed is that the
physical discharge of impurities contained in injected drugs
or adulterants can lead to endothelial injuring [23]. Whilst the
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tricuspid valve is the usual site of infection in IVDAs, pulmo-
nary and Eustachian valve infection may also be observed,
with left-sided IE being common in this group [27, 29].
Polymicrobial multivalve endocarditis infection on the
biventricular valve is uncommon; it is also generally de-
scribed in patients with prolonged IV infusion, in patients
with congenital heart disease with shunt, and particularly in
IVDAs [26, 30, 31]. It is also noteworthy that the greater
number of IE identified by echocardiography occurs on a
single valve; on two valves is less common; and on triple or
quadruple-valves has barely been addressed. Nevertheless,
multivalve endocarditis is an independent clinical entity
which has higher risks for the patient and generally with a
fatal outcome [30]. Thus, a polymicrobial multivalve IE,
although rare, represents an extremely elevated risk of high
morbidity as well as mortality.
According to Levine et al. [32], the pathogens and the
valves infected among patients with IVDA-IE may depend
on the type of illicit drug used, as they noted that the use of
certain drugs was associated with particular pathologies.More
recently, Jain et al. [33] demonstrated that tricuspid valve
endocarditis occurs more frequently in heroin users than in
other IVDAS. In the study of Saydain et al. [34], all patients
were heroin users, and the majority had right-sided endocar-
ditis; however, to establish the use of heroin as a key factor for
right-sided endocarditis it is necessary to carry out further
studies in a larger cohort of patients.
Saydain et al. [34] reported the outcome in a retrospective
study of 33 patients with IVDA-IE admitted to an ICU.
Accordingly, S. aureus was the more frequent pathogen, as it
was found in 31 patients (94 %), with 16 (52 %) being
methicillin resistant (MRSA). PE was detected in 5 (15 %)
patients with four having S. aureus + Streptococcus or S.
epidermidis or Acinetobacter or Candida. One patient had
Staphylococcus hominis + Corynebacterium and another pa-
tient had Streptococcus viridians. Initial empiric antibiotic
therapy was administrated in 29 patients and considered ap-
propriate based on the activity against the specific microor-
ganisms. MRSA are, thus, well-known nosocomial pathogens
with high levels of incidence in IE patients. Nevertheless,
community-associated methicillin resistant Staphylococcus
aureus (CA-MRSA) have been increasingly reported recently
and have become emerging pathogens of IE in adults and
children [35].
The initial selection of empiric antimicrobial therapy
should rely upon the suspicion of the infecting microorgan-
ism, type of drug and solvent used by the addict, and the
infection location [36]. In right-sided NVE, S. aureus must
always be taken into account, especially in IVDAs or ve-
nous catheter-related infection. Initially, therapy included
either penicillinase-resistant penicillins or vancomycin,
depending on the local prevalence of MRSA [32, 37]. In
the case of a patient being a pentazocine-tripelennamine
addict, infection with P. aeruginosa is usually correlated,
due to contamination during drug preparation for self-
administration, and an anti-Pseudomonas agent must be
administered [38]. If an IVDA is addicted to brown heroin
dissolved in lemon juice, Candida spp. (not C. albicans)
should be considered and antifungal treatment given [39]. In
the case of IVDAs with critical valve lesions right and/or
left-sided involvement, antibiotic treatment should comprise
protection against streptococci and enterococci [36]. Once
the causative organisms have been isolated and identified
therapy should be adjusted accordingly.
Polymicrobial endocarditis related to intravenous
drug abusers—IVDA-PE
Polymicrobial endocarditis is increasing, thus posing a huge
challenge to the medical community over the past decade, as
its outcome is often fatal [40]. The infection occurs primar-
ily and with increasing frequency in IVDAs with IE rather
than in non-IVDAs [26, 32]. It remains a rare and poorly
understood cardiac complication, with a predominance of
tricuspid valve involvement, but few data exist on IVDA-
PE. Nevertheless, in recent years, rates of PE among IVDAs
have increased, leaving a growing number of patients at risk
with health complications [41].
Besides IV drug use, fundamental cardiac structural abnor-
malities, prosthetic heart valves, and CVCs are among the
major risk factors for PE [42], but with low incidence. Al-
though, with the increasing broader employment of CVCs and
the current progress in medical devices, an increase in PE
incidence in the coming years is expected, which is already
starting to be noted [36, 43].
The most common combinations of organisms in PE in-
clude S. aureus and Streptococcus pneumoniae followed by S.
aureus and Pseudomonas aeruginosa. Candida parapsilosis
endocarditis carries a mortality rate of 45 %, and each infec-
tion with Candida or Pseudomonas per se carries a very high
mortality rate approaching 85 % and 80 %, respectively [41].
PE has a low survival rate, and patients with this type of
endocarditis need to be identified as soon as possible and
treated aggressively, with the appropriate antibiotics, if avail-
able, or surgery [44]. Therefore, combined therapy, medical
and surgical, represents the standard of care, but long-term
suppressive therapy duration in cases of polymicrobial fungal
endocarditis is still discussed.
Polymicrobial endocarditis also sustains a very high mortal-
ity rate (greater than 30 %) and an uncommonly large number
of patients (more than 50%) need heart surgery either to control
the infection or to repair cardiac failings resulting from the PE
infection. According to Saravolatz et al. [45], the prognosis
relies on the species rather than the number of microorganisms
isolated or antimicrobial and surgical therapy.
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In 1991, Adler et al. [46] reported the first case of an
IVDA with a tricuspid valve endocarditis involving seven
pathogens (Eikenella corrodens, Streptococcus intermedius,
Corynebacterium spp., Hemophilus parainfluenza, Bacte-
roids sp., Fusobacterium necrophorum and Eubacterium
lentum). Besides antimicrobial therapy, the patient required
surgery for the treatment of tricuspid valve endocarditis. In
this study it was demonstrated that the organism responsible
for infection may be neglected due to the presence of fas-
tidious pathogens in blood culture tests. Therefore, not all
the pathogens might be identified, with consequent treat-
ment failure and hemodynamic decompensation. This fact
suggests that, in many cases, PE may be not detected due to
the presence of such fastidious pathogens. If PE it is not
properly diagnosed, it will often result in the application of
an inadequate therapy, which will not be effective for eradi-
cation of the infection.
Raucher et al. [47] reported cases of PE in IVDAs with
Haemophilus parainfluenzae and other organisms of the
normal oral flora, such as S. aureus and commensal oral
streptococcal species. Oh et al. [31] presented a case of PE
caused by Actinomyces odontolytica, Veillonella species,
and Prevotella melaninogenica in a patient with a history
of injection drug abuse. It should be noted that the bacteria
implicated in this patient's PE are all anaerobes primarily
found in the human oral cavity. This means that the habit of
this patient of licking the needle to estimate the strength of
the injection exposed him to infection by these oral
microbes. The patient was successfully treated with a 6-
week course of penicillin G and metronidazole. This report
points out very clearly that contamination from non-skin
flora and PE should be considered in an IVDA with non-
sterile injection drug use practices. Indeed, another work
identifies the same organisms, as a part of a group of micro-
organisms that are particularly profuse in saliva and on the
dorsal and lateral surfaces of the tongue [48]. Therefore, the
patient's history and the absence of other microorganisms in
blood culture tests confirm that these bacteria were the
probable cause of the PE in that particular patient. This
highlights how important it is to be aware of the detailed
history of the patients injection drug use habits, because it
may reveal a risk factor for more abnormal infections and
thus enables modification or adjustment of the therapy of PE
[31]. In another case [49], a successful operative case of
tricuspid infective endocarditis in an IV drug user was
described, but despite IV drug use cessation, there were
additional recurrences. Six different microorganisms with
multiple portals of entry were identified, including one
episode of fungal endocarditis. This was the first case of
recurrent IE involving Candida dubliniensis in an HIV-
negative patient [49]. The achieved success in this case must
be pointed out, given that Candida IE or PE is uncommon
but often fatal [50] and, despite vigorous antifungal and
surgical therapy, mortality approaches 80 % in some cases
and hence, a better understanding of this infection is needed
[21, 51]. Taking into account that an effective treatment of a
bacterial endocarditis requires the use of high doses of anti-
biotics over extended periods of time, and frequently via the
IV route, it is thus expected that, in some cases, Candida
opportunistic infection will complicate bacterial endocarditis,
becoming a serious PE, due to Candida virulence.
Despite the advances in antimicrobial therapy and the
development of better diagnostic and surgical techniques,
PE is still a fatal infection. Therefore, an early diagnosis
of infective endocarditis is critical for the final outcome.
The use of new clinical criteria, emphasizing echocardi-
ography, is a positive guide for the practitioner correct
diagnosis.
Conclusion
The frequency of polymicrobial endocarditis is rising, with
significant morbidity and mortality rates and economic costs,
thus it is critical to widen the research on endocarditis. This in
turn will provide more information on the pathophysiology of
the disease, as well as novel and better treatment and prophy-
lactic strategies. These novel insights should help redefine
preventive and therapeutic strategies against PE. Infection by
staphylococci and streptococci is already being analyzed at the
molecular level and new ideas for antimicrobial agents and
prosthetic valve materials have been developed in recent
years.
A better understanding of the epidemiology and associated
risk factors of PE is required to develop more efficient thera-
pies for PE. Although, the factors associated with this disease
are poorly defined, essentially due to the rarity of PE as a
single institution. Therefore, PE studies are mostly derived
from single-site case studies and case reports.
In summary from this review it is possible to firmly con-
clude that:
& PE is still poorly understood and sustains a very high
mortality.
& PE occurs mainly on IVDAs.
& A predominance in the right side of the heart, often with
tricuspid valve involvement, is noticed.
& A meticulous knowledge of the patient's history is
critical for the adjustment of PE therapy, medical and/or
surgical.
& The most common combinations of organisms in PE are:
Staphylococcus aureus and Streptococcus pneumonia,
and Staphylococcus aureus and Pseudomonas aerugi-
nosa; and Candida spp. with bacteria.
& In IVDA-PE, the organisms are often anaerobes primarily
found in the human oral cavity.
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